Antidepressant Therapies Is Fastest Growing Segment Fueling The Growth Of Serotonin Norepinephrine Inhibitor Market

Serotonin Norepinephrine Inhibitor Market 


The Global Serotonin Norepinephrine Inhibitor Market is estimated to be valued at US$ 6.53 Bn in 2023 and is expected to exhibit a CAGR of 3.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.


Market Overview:
Serotonin-norepinephrine reuptake inhibitors (SNRIs) are a class of antidepressant medications that help treat major depressive disorder, generalized anxiety disorder, fibromyalgia and neuropathic pain by increasing levels of serotonin and norepinephrine in the brain. SNRIs have advantages over SSRIs as they act on both serotonin and norepinephrine rather than just serotonin alone.

Market key trends:
One of the emerging trends in the serotonin norepinephrine inhibitors market is the increased R&D activities for developing new treatment therapies combining multiple drug product types. Numerous clinical trials are currently underway to study the therapeutic efficacy of combining SNRIs with other anticonvulsants, antipsychotics or mood stabilizers for treating various mental health conditions including depression. Finding new drug combinations can help address treatment-resistant depression and provide alternative treatment options that work better with fewer side effects.

Segment Analysis
The global serotonin norepinephrine inhibitor market is dominated by the major depression segment. Major depression accounts for over 75% share of the overall serotonin norepinephrine inhibitor market. This is because serotonin norepinephrine inhibitors are primarily used for the treatment of major depressive disorder. Serotonin norepinephrine inhibitors have proven to be effective in alleviating symptoms associated with major depression such as feelings of worthlessness, guilt, inability to concentrate, and sadness.

Key Takeaways

The Global Serotonin Norepinephrine Inhibitor Market is expected to witness high growth, exhibiting a CAGR of 3.8% over the forecast period, due to increasing prevalence of depression globally. According to WHO, over 264 million people suffer from depression worldwide.

Regional analysis - North America dominates the global serotonin norepinephrine inhibitor market due to high awareness regarding mental health disorders and availability of advanced healthcare facilities in the region. However, Asia Pacific is expected to grow at the fastest pace during the forecast period owing to the presence of vast population base suffering from depression in countries such as China and India.

Key players - Key players operating in the serotonin norepinephrine inhibitor market are Pfizer Inc., Eli Lilly and Company, Allergan Plc., AstraZeneca Plc., Forest Laboratories Inc., Johnson & Johnson, Lundbeck A/S, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wyeth Pharmaceuticals Inc., Zydus Cadila Healthcare Ltd. Pfizer Inc. dominates the global market owing to its diversified product offering in antidepressants.

Read More - https://www.dailyprbulletin.com/serotonin-norepinephrine-inhibitor-market-projected-to-boost-the-growth-of-serotonin-norepinephrine-inhibitor-market/

Comments

Popular posts from this blog

Silicone Elastomers are Estimated to Witness High Growth Owing to Adoption in Medical Devices and Wearables

Global Lab-on-a-Chip and Microarrays (Biochip) Market Is Estimated To Witness High Growth Owing To Rising Demand for Personalized Medicine and Technological Advancements

The Automotive Wiring Harness Market is Estimated to Witness High Growth Owing to Increasing Demand for Electric Vehicles